Mainz Biomed B.V.
NASDAQ: MYNZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Guido Baechler
- Employees
- 19
- Headquarters
- Mainz, Germany
- IPO year
- 2021
- Market cap
- $14.7M
- Website
- https://mainzbiomed.com
Loading MYNZ…
Loading profile data…Frequently asked questions about MYNZ
What does Mainz Biomed B.V. (MYNZ) do?
Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for det...
Where does MYNZ trade?
Mainz Biomed B.V. (MYNZ) trades on the NASDAQ Capital Market.
What sector is MYNZ in?
Mainz Biomed B.V. (MYNZ) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Mainz Biomed B.V.?
Guido Baechler is the chief executive officer of Mainz Biomed B.V. (MYNZ).
Where is Mainz Biomed B.V. headquartered?
Mainz Biomed B.V. is headquartered in Germany.
Does MYNZ pay a dividend?
Mainz Biomed B.V. (MYNZ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MYNZ go public?
Mainz Biomed B.V. (MYNZ) completed its initial public offering in 2021.